ClinicalTrials.gg
TerminatedNCT05292196Updated Apr 20, 2025

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

A Phase 2 interventional study of TQC3721 suspension for inhalation and TQC3721 suspension placebo for inhalation in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 11 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Per sponsor request. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
13th of 17
59 · median 113
Started
2022
the only one that year
Phase 2
8 of 17
none open now
Registered
3rd of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 13th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 2, and was the 3rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects. This is a randomized, double-blind, placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721 suspension/placebo at different doses in patients with moderate to severe chronic obstructive pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Sign the form before the trial, fully understand the content, process and possible adverse reactions of the test;
  • 2 Capable of using the study nebulizer correctly and complying with all study restrictions and procedures;
  • 3 Aged between 18 and 75 years old, both men and women;
  • 4 (BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value) and body weight is ≥45kg;
  • 5 Subjects have no pregnancy plan and have voluntarily taken effective measures for at least 1 month after being screened to the last use of the study drug;
  • 6 12-lead with corrected ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no morphologic and other clinical significant abnormalities that the investigator considered inappropriate for the study;
  • 7 Ability to perform acceptable and reproducible spirometry;
  • 8 Patients previously treated with LAMA or LABA who had evidence of stable use for at least 3 months prior to screening and agreed to continue use during the study period;
  • 9 Capable of withholding LAMA or LABA( Twice-Daily maintenance LAMA or LABA for at least 24 hours and Once-Daily maintenance LAMA or LABA for at least 48 hours) and SAMA、SABAs(at least 4 hours)prior to initiation of any spirometry;
  • 10 According to the 2020 GOLD Guidelines, Post-bronchodilator spirometry at screening must demonstrate /FVC ratio of ≤0.70 and FEV1 must be ≥30 % to ≤80% of predicted normal;
  • 11 Current or former cigarette smokers with a history of cigarette smoking ≥10 pack years (eg, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years, former cigarette smokers should stop smoke at least 6 months before visit 1).

Exclusion criteria

Exclusion Criteria:

  • 1 Intolerance to salbutamol or this product.
  • 2 ≥1 hospitalization for treatment within 6 months prior to screening.
  • 3 Antibiotic treatment for lower respiratory tract infection within 3 months prior to screening.
  • 4 Use of prohibited medications within the time intervals.
  • 5 Patients who were currently diagnosed with asthma, active tuberculosis, lung cancer and other active lung diseases and were considered unsuitable for the study.
  • 6 Previous lung resection or lung reduction surgery.
  • 7 Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Screening and remains stable during the study.
  • 8 A history of drug or alcohol abuse in the past 3 years (14 units of alcohol consumed per week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine).
  • 9 Have participated in a clinical trial within one month prior to screening or within 5 half-lives of the drug, whichever is the longer.
  • 10 Women who are breast-feeding.
  • 11 A history of myocardial infarction, congestive heart failure, and unstable or uncontrolled hypertension (systolic blood pressure ≥160mmHg and diastolic blood pressure ≥100mmHg after drug control) within 6 months prior to screening.
  • 12 History of of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.
  • 13 (ALT) or aspartate aminotransferase(AST)≥ 2 x (ULN), or other abnormal test results were deemed unsuitable for inclusion by the investigator.
  • 14 Required use of oxygen therapy, even on an occasional basis.
  • 15 Other conditions that the investigator considered inappropriate for participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    TQC3721 suspension for inhalation

    TQC3721 suspension for inhalation, four weeks as a treatment cycle.

    Drug: TQC3721 suspension for inhalation

  • Placebo comparator
    TQC3721 suspension placebo for inhalation

    TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.

    Drug: TQC3721 suspension placebo for inhalation

Interventions

  • TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor

  • DrugTQC3721 suspension placebo for inhalation

    TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor

06

What researchers measure

Primary outcomes

  1. The peak of Forced Expiratory Volume(FEV1)

    Change of the maximum value of FEV1 was determined from baseline to 30minute, 1hour, 2hour and 3hour after medication at week four

    Time frame: From the enrollment of the subjects to four weeks after administration

Secondary outcomes

  1. Morning trough FEV1

    The FEV1 was determined before administration

    Time frame: From the enrollment of the subjects to four weeks after administration

  2. Average FEV1

    Average FEV1 twelve hours after administration

    Time frame: From the enrollment of the subjects to four weeks after administration

  3. COPD Assessment Test (CAT)

    Mean Change From Baseline in COPD Assessment Test (CAT) Scoring at Week four. The score range is zero to Fourty points (zero to ten is minor influence; eleven to twenty are moderate; twenty one to thirty are classified as severe impact; thirty one to forty is very severe), and more than ten is more symptoms.

    Time frame: From enrollment to four weeks after administration

  4. Rescue medication

    Frequency of Rescue medication use during the study

    Time frame: From baseline to four weeks after administration

  5. Incidence of adverse events

    The Incidence of adverse events as assessed by CTCAE (Common Terminology Criteria for Adverse Events) v5.0

    Time frame: from baseline to four weeks after administration

  6. Number of adverse events related to the study drug

    The number of adverse events associated with the study drug assessed by CTCAE V5.0

    Time frame: from baseline to four weeks after administration

  7. Incidence of adverse events associated with the study drug

    Incidence of adverse events associated with the study drug as assessed by CTCAE V5.0

    Time frame: from baseline to four weeks after administration

07

Study locations

11 sites
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400000, China
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730700, China
  • The Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524023, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Ha'erbin, Heilongjiang 150001, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jianxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110002, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
  • Mianyang Central Hospital
    Mianyang, Sichuan 621099, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jan 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Mar 23, 2022
StartActual
May 20, 2022
Primary completionActual
Jan 11, 2023
CompletionActual
Dec 5, 2023
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05292196
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
May 20, 2022
Primary completion
Jan 11, 2023
Completion
Dec 5, 2023
Last update
Apr 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3721

Start the discussion